Page last updated: 2024-11-12
belactosin c
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
belactosin C: isolated from Streptomyces; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 10666031 |
CHEMBL ID | 1783833 |
SCHEMBL ID | 3448978 |
MeSH ID | M0360003 |
Synonyms (3)
Synonym |
---|
CHEMBL1783833 |
belactosin c |
SCHEMBL3448978 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1225669 | Inhibition of chymotrypsin-like activity of rabbit 20S proteasome using Suc-LLVY-AMC as substrate after 2 hrs by fluorescence assay | 2015 | Journal of natural products, Apr-24, Volume: 78, Issue:4 | Cystargolides, 20S Proteasome Inhibitors Isolated from Kitasatospora cystarginea. |
AID599460 | Antiproliferative activity against human HeLaS3 cells after 72 hrs | 2009 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 19, Issue:12 | Synthesis and biological evaluation of boron peptide analogues of Belactosin C as proteasome inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (58.33) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.53
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 12 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |